SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases will be the subject of three research abstracts at the Alzheimer’s Association International Conference^® 2020 (AAIC^®). The largest international meeting dedicated to advancing dementia science, AAIC will be held as a virtual event this year from July 27-31, 2020.

The accepted abstracts further document the role that P. gingivalis, the bacterium most commonly associated with chronic periodontal disease, plays as a driver of Alzheimer’s-like neuropathology, and highlight the potential of atuzaginstat (formerly COR388), Cortexyme’s investigational medicine to target the virulence factor proteases released by the bacterium. In a Developing Topics poster, Cortexyme researchers, in collaboration with researchers at The Forsyth Institute, will present preclinical data about the role of P. gingivalis in the acceleration of atherosclerosis, the underlying condition of cardiovascular disease that frequently presents alongside Alzheimer’s, and for the first time, the potential utility of atuzaginstat in attenuating this effect.

“Our research team continues to generate compelling data documenting P. gingivalis’ role in driving Alzheimer’s-like neuropathology, and of the potential for atuzaginstat to slow or stop Alzheimer’s disease progression,” said Casey Lynch, Cortexyme’s chief executive officer, co-founder, and chair. “With several significant clinical milestones anticipated in the coming quarters, we are looking forward to sharing our latest findings with the international Alzheimer’s research community at AAIC next week.”

The full roster of Cortexyme presentations expected at the meeting is as follows:

[Abstract 44023P1] “Comprehensive Alzheimer’s pathology is induced by Porphyromonas gingivalis infection: COR388 (atuzaginstat) and other gingipain inhibitors protect against synaptic loss”

Florian Ermini, Ph.D., et al.

Poster: Basic Science and Pathogenesis – Molecular and Cell Biology

Presented Monday, July 27, 2020

[Abstract 47058P3] “Targeting Porphyromonas gingivalis to treat Alzheimer’s disease and comorbid cardiovascular disease”

Florian Ermini, Ph. (Read more…)D., et al.

Developing Topic Poster: Drug Development

Presented Wednesday, July 29, 2020

[Abstract 40578P3] “COR388 (atuzaginstat), a novel gingipain inhibitor, decreases fragmentation of ApoE in the central nervous system of Alzheimer’s disease patients”

Debasish Raha et al.

Poster: Drug Development – Human Trials

Presented Wednesday, July 29, 2020

About Forsyth Institute

Founded in 1910, The Forsyth Institute is the only independent research organization in the United States dedicated to understanding the important connections between oral health and overall wellness. Forsyth scientists have identified and characterized many of the oral bacteria that play role in oral diseases and have capacity to increase risk for other diseases in the body. Forsyth Institute is a not-for-profit organization that is also committed to treating underserved populations in local communities and on a national and global scale. To learn more about Forsyth, visit www.forsyth.org

About Cortexyme, Inc.

Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our business plans and prospects, the translation to humans of pre-clinical data; the pre-clinical results for our product candidates, the timing and success of our clinical trials and related data, the potential of atuzaginstat to treat Alzheimer’s disease and cardiovascular disease, our ability to fund planned operating and capital expenditures, the timing of announcements and updates relating to our clinical trials and related data, the timing of and our ability to enroll patients into our clinical trials, and the potential therapeutic benefits, safety and efficacy of our product candidate or library of compounds. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 16, 2020, our Quarterly Report on Form 10-Q filed with the SEC on May 12, 2020, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.

Contacts

Media Contact:
Hal Mackins

For Cortexyme, Inc.

[email protected]
(415) 994-0040

Investor Contact:
Chris Lowe

Chief Financial Officer

Cortexyme, Inc.

[email protected]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases will be the subject of three research abstracts at the Alzheimer’s Association International Conference^® 2020 (AAIC^®). The largest international meeting dedicated to advancing dementia science, AAIC will be held as a virtual event this year from July 27-31, 2020.

The accepted abstracts further document the role that P. gingivalis, the bacterium most commonly associated with chronic periodontal disease, plays as a driver of Alzheimer’s-like neuropathology, and highlight the potential of atuzaginstat (formerly COR388), Cortexyme’s investigational medicine to target the virulence factor proteases released by the bacterium. In a Developing Topics poster, Cortexyme researchers, in collaboration with researchers at The Forsyth Institute, will present preclinical data about the role of P. gingivalis in the acceleration of atherosclerosis, the underlying condition of cardiovascular disease that frequently presents alongside Alzheimer’s, and for the first time, the potential utility of atuzaginstat in attenuating this effect.

“Our research team continues to generate compelling data documenting P. gingivalis’ role in driving Alzheimer’s-like neuropathology, and of the potential for atuzaginstat to slow or stop Alzheimer’s disease progression,” said Casey Lynch, Cortexyme’s chief executive officer, co-founder, and chair. “With several significant clinical milestones anticipated in the coming quarters, we are looking forward to sharing our latest findings with the international Alzheimer’s research community at AAIC next week.”

The full roster of Cortexyme presentations expected at the meeting is as follows:

[Abstract 44023P1] “Comprehensive Alzheimer’s pathology is induced by Porphyromonas gingivalis infection: COR388 (atuzaginstat) and other gingipain inhibitors protect against synaptic loss”

Florian Ermini, Ph.D., et al.

Poster: Basic Science and Pathogenesis – Molecular and Cell Biology

Presented Monday, July 27, 2020

[Abstract 47058P3] “Targeting Porphyromonas gingivalis to treat Alzheimer’s disease and comorbid cardiovascular disease”

Florian Ermini, Ph. (Read more…)D., et al.

Developing Topic Poster: Drug Development

Presented Wednesday, July 29, 2020

[Abstract 40578P3] “COR388 (atuzaginstat), a novel gingipain inhibitor, decreases fragmentation of ApoE in the central nervous system of Alzheimer’s disease patients”

Debasish Raha et al.

Poster: Drug Development – Human Trials

Presented Wednesday, July 29, 2020

About Forsyth Institute

Founded in 1910, The Forsyth Institute is the only independent research organization in the United States dedicated to understanding the important connections between oral health and overall wellness. Forsyth scientists have identified and characterized many of the oral bacteria that play role in oral diseases and have capacity to increase risk for other diseases in the body. Forsyth Institute is a not-for-profit organization that is also committed to treating underserved populations in local communities and on a national and global scale. To learn more about Forsyth, visit www.forsyth.org

About Cortexyme, Inc.

Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our business plans and prospects, the translation to humans of pre-clinical data; the pre-clinical results for our product candidates, the timing and success of our clinical trials and related data, the potential of atuzaginstat to treat Alzheimer’s disease and cardiovascular disease, our ability to fund planned operating and capital expenditures, the timing of announcements and updates relating to our clinical trials and related data, the timing of and our ability to enroll patients into our clinical trials, and the potential therapeutic benefits, safety and efficacy of our product candidate or library of compounds. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 16, 2020, our Quarterly Report on Form 10-Q filed with the SEC on May 12, 2020, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.

Contacts

Media Contact:
Hal Mackins

For Cortexyme, Inc.

[email protected]
(415) 994-0040

Investor Contact:
Chris Lowe

Chief Financial Officer

Cortexyme, Inc.

[email protected]